Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Zai Lab Ltd ( (HK:9688) ) is now available.
Zai Lab has granted share options, restricted share units and performance share units to its chairperson and chief executive officer, Dr. Samantha Du, under its 2024 Equity Incentive Plan. The package includes 353,430 American depositary share options, equivalent to 3,534,300 underlying shares, and 32,419 restricted share units, or 324,190 shares, with the options priced at US$19.34 per ADS and a 10-year term.
The options will vest in four equal annual tranches over four years, contingent on Dr. Du’s continued employment, with no additional performance targets or clawback mechanisms attached. The board’s compensation committee said the structure is in line with market practice and the company’s historical approach, underscoring Zai Lab’s strategy of using equity-based incentives to retain key leadership and align them with shareholder interests as it executes its growth plans.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$15.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong and on Nasdaq. The company focuses on developing and commercializing innovative medicines, with its leadership and equity incentive structures designed to align management interests with long-term shareholder value in global healthcare markets.
Average Trading Volume: 10,274,395
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.48B
Learn more about 9688 stock on TipRanks’ Stock Analysis page.